CEN Case Reports

, Volume 3, Issue 1, pp 86–89 | Cite as

Increased antiangiogenetic factors in severe proteinuria without hypertension in pregnancy: is kidney biopsy necessary?

  • Takako Ohmaru
  • Akihide Ohkuchi
  • Shigeaki Muto
  • Chikako Hirashima
  • Shigeki Matsubara
  • Mitsuaki Suzuki
Case Report


Acute onset of severe proteinuria during pregnancy obliges physicians to clinically discriminate between gestational proteinuria (GP) and new onset of nephritis. A multiparous woman developed severe proteinuria (5.8 g/day) without hypertension at 32 weeks of gestation. We measured the maternal level of soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sEng), which were extremely high (41.3 and 54.8 ng/ml, respectively), leading us to consider this condition as GP rather than acute onset of nephritis. Thus, we did not perform a kidney biopsy and did not administer a steroid agent. Non-reassuring fetal status required emergency Cesarean section at 33 weeks. Proteinuria decreased to 0.36 g/day at 12 weeks after delivery, and finally disappeared 26 weeks postpartum. Measurement of sFlt-1 and sEng in a pregnant woman with severe proteinuria without hypertension may assist in differential diagnosis of GP from acute onset of nephritis, and thus help to decide whether to perform kidney biopsy during pregnancy.


Gestational proteinuria Nephritis Pregnancy Soluble fms-like tyrosine kinase 1 Soluble endoglin 


  1. 1.
    Piccoli GB, Daidola G, Attini R, Parisi S, Fassio F, Naretto C, Deagostini MC, Castelluccia N, Ferraresi M, Roccatello D, Todros T. Kidney biopsy in pregnancy: evidence for counselling? A systematic narrative review. BJOG. 2013;120:412–27.PubMedCrossRefGoogle Scholar
  2. 2.
    Ohkuchi A, Hirashima C, Matsubara S, Suzuki H, Takahashi K, Usui R, Suzuki M. Serum sFlt: PlGF ratio, PlGF, and soluble endoglin levels in gestational proteinuria. Hypertens Pregnancy. 2009;28:95–108.PubMedCrossRefGoogle Scholar
  3. 3.
    Masuyama H, Suwaki N, Nakatsukasa H, Masumoto A, Tateishi Y, Hiramatrsu Y. Circulating angiogenic factors in preeclampsia, gestational proteinuria, and preeclampsia superimposed on chronic glomerulonephritis. Am J Obstet Gynecol. 2006;194:551–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Hirashima C, Ohkuchi A, Takahashi K, Suzuki H, Yoshida M, Ohmaru T, Eguchi K, Ariga H, Matsubara S, Suzuki M. Gestational hypertension as a subclinical preeclampsia in view of serum levels of angiogenesis-related factors. Hypertens Res. 2011;34:212–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Hirashima C, Ohkuchi A, Matsubara S, Suzuki H, Takahashi K, Usui R, Suzuki M. Alteration of serum soluble endoglin levels after the onset of preeclampsia is more pronounced in women with early-onset. Hypertens Res. 2008;31:1541–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672–83.PubMedCrossRefGoogle Scholar
  7. 7.
    Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA, CPEP Study Group. Soluble endoglin and other circulating angiogenic factors in preeclampsia. N Engl J Med. 2006;355:992–1005.PubMedCrossRefGoogle Scholar
  8. 8.
    Ohkuchi A, Hirashima C, Matsubara S, Suzuki H, Takahashi K, Arai F, Watanabe T, Kario K, Suzuki M. Alterations in placental growth factor levels before and after the onset of preeclampsia are more pronounced in women with early onset severe preeclampsia. Hypertens Res. 2007;30:151–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Ohkuchi A, Hirashima C, Matsubara S, Takahashi K, Matsuda Y, Suzuki M. Threshold of soluble fms-like tyrosine kinase 1/placental growth factor ratio for the imminent onset of preeclampsia. Hypertension. 2011;58:859–66.PubMedCrossRefGoogle Scholar
  10. 10.
    Unverdi S, Ceri M, Unverdi H, Yilmaz R, Akcay A, Duranay M. Postpartum persistent proteinuria after preeclampsia: a single-center experience. Wien Klin Wochenschr. 2013;125:91–5.PubMedCrossRefGoogle Scholar
  11. 11.
    Morikawa M, Yamada T, Yamada T, et al. Pregnancy outcome of women who developed proteinuria in the absence of hypertension after mid-gestation. J Perinat Med. 2008;36:419–24.PubMedCrossRefGoogle Scholar
  12. 12.
    Suzuki H, Ohkuchi A, Matsubara S, Takei Y, Murakami M, Shibuya M, Suzuki M, Sato Y. Effect of recombinant placental growth factor 2 on hypertension induced by full-length mouse soluble fms-like tyrosine kinase 1 adenoviral vector in pregnant mice. Hypertension. 2009;54:1129–35.PubMedCrossRefGoogle Scholar
  13. 13.
    Sato K. A proposal for a new definition and classification of “pregnancy induced hypertension (PIH)” (2004). In: Japan Society for the Study of Toxemia of Pregnancy, editor. Historical perspective of study of pregnancy-induced hypertension in Japan. Tokyo: Medical View Co; 2005. p. 54–87.Google Scholar

Copyright information

© Japanese Society of Nephrology 2013

Authors and Affiliations

  • Takako Ohmaru
    • 1
  • Akihide Ohkuchi
    • 1
  • Shigeaki Muto
    • 2
  • Chikako Hirashima
    • 1
  • Shigeki Matsubara
    • 1
  • Mitsuaki Suzuki
    • 1
  1. 1.Department of Obstetrics and GynecologyJichi Medical University School of MedicineShimotsuke-shiJapan
  2. 2.Division of Nephrology, Department of Internal MedicineJichi Medical University School of MedicineShimotsuke-shiJapan

Personalised recommendations